Document is current
Any future updates will be listed below
-
Authors
Povoa, Pedro https://orcid.org/0000-0002-7069-7304
Coelho, Luís https://orcid.org/0000-0003-0701-3624
Carratala, Jordi https://orcid.org/0000-0003-3209-2563
Cawcutt, Kelly https://orcid.org/0000-0003-3586-0951
Cosgrove, Sara E. https://orcid.org/0000-0001-9458-4331
Ferrer, Ricard https://orcid.org/0000-0002-4859-4747
Gomez, Carlos A. https://orcid.org/0000-0001-5486-5710
Klompas, Michael https://orcid.org/0000-0001-8641-4498
Lisboa, Thiago https://orcid.org/0000-0003-4306-2212
Martin-Loeches, Ignacio https://orcid.org/0000-0002-5834-4063
Nseir, Saad https://orcid.org/0000-0002-7618-0357
Salluh, Jorge I. F. https://orcid.org/0000-0002-8164-1453
Scherger, Sias https://orcid.org/0000-0003-3299-855X
Sweeney, Daniel A. https://orcid.org/0000-0002-5398-3528
Kalil, Andre C. https://orcid.org/0000-0002-6489-6294
-
Funding
Funding for this research was provided by:
Universidade Nova de Lisboa
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 8 April 2025
First Online: 24 May 2025
Declarations
:
: PP received fees for lecture from Gilead and Mundipharma, consulting from MSD and Biocodex. KC received fees for lectures and advisory board from BD. RF received fees as speaker and/or advisor for Pfizer, MSD, Shionogi, Gilead, GE, AOP Health, Grifols, Thermofisher, Estor, Toray, BD, Menarini, Viatris. CAG received consultation fees from Karius Inc Diagnostics. MK has grants from CDC, AHRQ; contracts from Massachusetts Department of Public Health; royalties from UpToDate. IML received fees lectures and advisory board MSD, Menarini, Biomerieux, Mundipharma, Gilead, and Thermofisher. SN received consultation fees from Mundipharma, and lecture fees from MSD, Biomérieux, Pfizer, Fisher and Peykel, Shionogi, and Medtronic. LC, JC, SEC, TL, JIFS, SS, DS, AK declare no conflict of interest.
